3,000 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Flower City Capital

Flower City Capital acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,000 shares of the company’s stock, valued at approximately $254,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. XTX Topco Ltd raised its position in shares of Axsome Therapeutics by 177.9% in the second quarter. XTX Topco Ltd now owns 11,205 shares of the company’s stock valued at $902,000 after buying an additional 7,173 shares during the last quarter. Sei Investments Co. grew its stake in Axsome Therapeutics by 13.9% during the 2nd quarter. Sei Investments Co. now owns 40,624 shares of the company’s stock valued at $3,270,000 after acquiring an additional 4,970 shares in the last quarter. HighVista Strategies LLC raised its holdings in Axsome Therapeutics by 28.2% in the 2nd quarter. HighVista Strategies LLC now owns 62,192 shares of the company’s stock valued at $5,006,000 after acquiring an additional 13,665 shares during the last quarter. Hood River Capital Management LLC lifted its stake in Axsome Therapeutics by 5.4% in the 2nd quarter. Hood River Capital Management LLC now owns 549,066 shares of the company’s stock worth $44,200,000 after purchasing an additional 28,316 shares in the last quarter. Finally, Bank of Montreal Can acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $849,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AXSM has been the topic of a number of analyst reports. Royal Bank of Canada lifted their price objective on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. HC Wainwright reiterated a “buy” rating on shares of Axsome Therapeutics in a report on Tuesday, December 31st. Mizuho dropped their price objective on shares of Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, December 31st. Truist Financial lifted their target price on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Finally, StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $130.69.

Axsome Therapeutics Trading Down 1.9 %

AXSM opened at $91.93 on Monday. The business has a fifty day moving average price of $92.27 and a 200 day moving average price of $89.53. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $105.00. The stock has a market capitalization of $4.45 billion, a price-to-earnings ratio of -14.08 and a beta of 1.04.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period in the prior year, the firm earned ($1.32) earnings per share. Sell-side analysts expect that Axsome Therapeutics, Inc. will post -4.61 earnings per share for the current fiscal year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.